ArticlePLoS neglected tropical diseases2025
Equitable access to essential medicines to treat neglected tropical diseases: Latest developments from the World Health Organization (WHO).
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of essential drug lists: concordance, differences, and the need for core lists in times of crisis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In July 2023, the World Health Organization (WHO) released the 23rd Model List of Essential Medicines (EML) for adults and the 9th Model List of EML for children. These lists serve as global references for essential medicines that should be universally available, accessible, and affordable. This editorial explores recent updates to the WHO EML lists, with a particular focus on medicines addressing neglected tropical diseases (NTDs). We discuss the persistent barriers to equitable access, including economic, regulatory, and logistical challenges; highlight global initiatives aimed at improving accessibility; and propose strategies to bridge the gap in essential medicine access. We emphasize the need for international collaboration, increased funding for research institutions, pharmaceutical companies, and global health initiatives to support the development of novel treatments for NTDs, and innovative distribution approaches to ensure these medications reach underserved populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.